New Insights Show ASCL1’s Role in Neuroendocrine Prostate ...
14 hours ago · This capacity, known as lineage plasticity, allows prostate cancer cells to transform from adenocarcinoma into neuroendocrine prostate cancer, a much more aggressive and deadly form of the disease. The cellular shapeshifting causes neuroendocrine prostate cancer to develop in 15% of patients receiving androgen receptor therapy.
FDA approves new treatment for advanced prostate cancer
Jul 12, 2023 · In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
Xtandi Approved for High-Risk Prostate Cancer - NCI
Jan 5, 2024 · Enzalutamide (Xtandi) can now be used alone or combined with leuprolide to treat some people with prostate cancer who have had a biochemical recurrence.
FDA Approves Promising Therapy for Advanced Prostate Cancer ...
Mar 23, 2022 · Prostate cancer treatment took a major step forward today as the U.S. Food and Drug Administration approved a new therapy that zeros in on cancer cells to destroy them. The treatment, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface called PSMA (prostate-specific ...
Immune Sensitivity Links Race and Survival After Prostate ...
1 day ago · 919-943-3819 Email. DURHAM, N.C. – Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is described in a new study by researchers at Duke Cancer Institute and published recently in the journal Cancer ...
A Promising New Therapy for Advanced Prostate Cancer
Jun 3, 2021 · Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
Promising new options for treating aggressive prostate cancer
Cedars-Sinai Cancer investigators have identified two promising new treatment options for men with recurrent prostate cancer -- both of which helped patients live longer without their disease...